Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457 - Riyadh 14511, Saudi Arabia.
Eur J Med Chem. 2010 Oct;45(10):4578-86. doi: 10.1016/j.ejmech.2010.07.020. Epub 2010 Aug 8.
Tuberculosis (TB) remains among the world's great public health challenges. Worldwide resurgence of TB is due to two major problems: the AIDS epidemic, which started in the mid-1980s, and the outbreak of multidrug resistant (MDR) TB. Thus, there is an urgent need for anti-TB drugs with enhanced activity against MDR strains. In recent years, Schiff bases of 1H-indole-2,3-diones are reported to exhibit anti-TB activity. On the other hand, several quinolone antibacterial agents have been examined as inhibitors of TB, as well as other mycobacterial infections. Accordingly, the current work involved design and synthesis of Schiff bases of nalidixic acid carbohydrazide and isatin derivatives (5,6a-f and 7,8a-c). Structures of the synthesized derivatives were confirmed on the bases of spectral methods of analyses. Anti-TB activity of the synthesized derivatives was investigated against four Mycobacterium strains: Mycobacterium intercellulari, Mycobacterium xenopi, Mycobacterium cheleneo and Mycobacterium smegmatis. Modest anti-TB activity was observed within the investigated compounds, however, compound 5f revealed potent anti-TB activity with MIC 0.625 microg/ml, which is 20 times greater than the reference drug isoniazid, INH, (MIC = 12.5 microg/ml). A hypothetical pharmacophore model was built using Molecular Operating Environment (MOE) program and 10 compounds structurally related to the synthesized ones with reported anti-TB activity. The Pharmacophoric model built revealed the necessity of the following pharmacophoric features for anti-TB activity: aromatic center, hydrogen bond acceptor/metal ligator center, hydrogen bond donor center and aromatic center/hydrophobic area. Theses features were consistent with the found anti-TB activity of the tested compounds.
结核病(TB)仍然是全球重大公共卫生挑战之一。全球范围内结核病的死灰复燃归因于两个主要问题:20 世纪 80 年代中期开始的艾滋病流行,以及耐多药(MDR)结核的爆发。因此,迫切需要具有增强的抗 MDR 株活性的抗结核药物。近年来,1H-吲哚-2,3-二酮的席夫碱被报道具有抗结核活性。另一方面,几种喹诺酮类抗菌药物已被研究为结核以及其他分枝杆菌感染的抑制剂。因此,目前的工作涉及到设计和合成纳氟沙星糖基肼和色酮衍生物的席夫碱(5、6a-f 和 7、8a-c)。根据光谱分析方法确定了合成衍生物的结构。对合成衍生物进行了对四种分枝杆菌菌株的抗结核活性研究:细胞内分枝杆菌、非洲分枝杆菌、龟分枝杆菌和耻垢分枝杆菌。在所研究的化合物中观察到了适度的抗结核活性,然而,化合物 5f 表现出了强大的抗结核活性,MIC0.625μg/ml,是参考药物异烟肼(INH)的 20 倍(MIC=12.5μg/ml)。使用分子操作环境(MOE)程序构建了一个假设的药效团模型,并使用具有报道的抗结核活性的 10 种与合成化合物结构相关的化合物。构建的药效团模型揭示了抗结核活性的以下药效团特征的必要性:芳香中心、氢键受体/金属配体中心、氢键供体中心和芳香中心/疏水区。这些特征与测试化合物的抗结核活性一致。